Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on 18F-DOPA PET Images
Authors:
- Jing QianJQJing Qian
- Deanna HasenauerDHDeanna Hasenauer
- William G. BreenWBWilliam G. Breen
- Paul D. BrownPBPaul D. Brown
- Christopher H. HuntCHChristopher H. Hunt
- Mark S. JacobsonMJMark S. Jacobson
- Derek R. JohnsonDJDerek R. Johnson
- Timothy J. KaufmannTKTimothy J. Kaufmann
- Bradley J. KempBKBradley J. Kemp
- Sani H. KizilbashSKSani H. Kizilbash
- Val J. LoweVLVal J. Lowe
- Michael W. RuffMRMichael W. Ruff
Open Access
Abstract
Background: Post-treatment prognosis and monitoring are critical for determining the timing of salvage treatment in glioblastoma patients but has been challenging due to difficulties differentiating progression from treatment effects in conventional images. This exploratory study aimed to establish the correlation of radiomics image features from time series of amino acid tracer 18F-DOPA PET images, with outcomes, using machine learning and dimension reduction analysis. Methods: 18F-DOPA PET images were collected for a patient cohort with wild-type IDH and unmethylated MGMT who underwent dose-escalated radiation therapy. Quantitative features were derived from the high uptake region (T/N > 2.0) in pre- and post-radiation therapy follow-up 18F-DOPA PET images. A customized workflow was utilized for pre-selecting predictive features, followed by manifold learning. Machine learning algorithms were employed to establish associations between imaging features and remaining survival (RS), defined as the time between a follow-up scan and date of death. Results: The ML models exhibited 81–83% ROC_AUC in predicting RS evaluated on an independent test dataset. A RS map is proposed for monitoring tumor alterations through serial 18F-DOPA PET scans, demonstrating superior sensitivity and better correlation with survival compared to the RANO criteria. Conclusions: Our study demonstrates that ML models utilizing FU 18F-DOPA PET images have the potential to effectively predict future survival outcomes in patients with glioblastoma treated with dose-escalated radiation therapy. The capability to assess changes in tumor over time through imaging can potentially assist in patient stratification and the selection of salvage treatments, while also aiding in distinguishing treatment effects from genuine tumor progression.Keywords
Funding Information
- National Cancer Institute of the National Institutes of Health (R01CA178200)
This publication has 46 references indexed in Scilit:
- Added value of [18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patientsJournal of Neuro-Oncology, 2022
- Repeated amino acid PET imaging for longitudinal monitoring of brain tumorsClinical and Translational Imaging, 2022
- Benchmarking Various Radiomic Toolkit Features While Applying the Image Biomarker Standardization Initiative toward Clinical Translation of Radiomic AnalysisJournal of Digital Imaging, 2021
- Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Pseudoprogression of brain tumorsJournal of Magnetic Resonance Imaging, 2018
- 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional studyJournal of Neuro-Oncology, 2018
- Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed GlioblastomaJAMA Oncology, 2018
- Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006